Top Markets
Coin of the day
Vaxcell-Bio Therapeutics Co., Ltd. Vaxcell-Bio Therapeutics Co., Ltd.

Vaxcell-Bio Therapeutics Co., Ltd.

323990
Rank in Stocks #24157
Established in 2010, Vaxcell-Bio Therapeutics Co., Ltd. specializes in the... Established in 2010, Vaxcell-Bio Therapeutics Co., Ltd. specializes in the research, development, and commercialization of immune cell-based therapies designed to treat cancer, primarily operating within South Korea. The company's main base of operations is located in Hwasun-eup, South Korea.
Share Price
$2.77
Last synced: 2026-08-21
Market Cap
$64.26M
Change (1 day)
-4.64%
Change (1 year)
-57.45%
Country
KR
Trade Vaxcell-Bio Therapeutics Co., Ltd. (323990)

Category

P/E ratio for Vaxcell-Bio Therapeutics Co., Ltd. (323990)
P/E ratio as of 2026 TTM: 0
According to Vaxcell-Bio Therapeutics Co., Ltd. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Vaxcell-Bio Therapeutics Co., Ltd. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
29.20 -
US
30.62 -
NL
-7.93 -
US
32.46 -
AU
- -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.